Aftab RA, et al. - In this single center, prospective, single-blind randomized trial, researchers estimated survival in post-dialysis euvolemic hypertensive patients in relation to losartan 50 mg administration. This medication was administered to patients every other day. Using randomization, the patients were assigned to the standard or intervention arm. Participants were observed over 12 months duration. According to the findings, treatment with losartan 50 mg brought about no statistical significant difference in 1 year survival of post-dialysis euvolemic hypertensive patients.